Peripheral T-Cell Lymphoma Market to Observe Growth at a CAGR of 4.9% in the US by 2032 | DelveInsight
November 21, 2023 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Peripheral T-Cell Lymphoma Market to Observe Growth at a CAGR of 4.9% in the US by 2032 | DelveInsight The rapid growth in the peripheral T-cell...
Autolus Therapeutics Presents Positive Results from AUTO4 in Relapsed/Refractory TRBC1-Positive Peripheral T-Cell Lymphoma
June 16, 2023 07:00 ET
|
Autolus Therapeutics plc
At the highest dose 4 out of 4 PTCL patients achieved a response using the original manufacturing process (Process A)Ongoing complete metabolic responses in 2 out of 4 patients at 15 and 18-months...
Global T-cell Lymphoma Market to Surpass US$ 2,495.4 Million by 2028, Says Coherent Market Insights (CMI)
December 20, 2021 09:00 ET
|
CMI
SEATTLE, Dec. 20, 2021 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global T-cell lymphoma market is estimated to be valued at US$ 1,627.1 million in 2021 and is expected to...
Rhizen Pharmaceuticals S.A. receives FDA orphan-drug designation for Tenalisib (RP6530) for treatment of peripheral T-cell lymphoma (PTCL)
December 22, 2017 08:00 ET
|
Rhizen Pharmaceuticals SA
La Chaux-de-Fonds, Switzerland, Dec. 22, 2017 (GLOBE NEWSWIRE) -- Rhizen Pharmaceuticals S.A., today announced that the U.S. Food and Drug Administration (FDA) has granted orphan-drug designation...
Kura Oncology Presents Preclinical Data Demonstrating Significant Anti-Tumor Activity of KO-947 and KO-539
April 05, 2017 08:00 ET
|
Kura Oncology, Inc.
LA JOLLA, Calif., April 05, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company focused on the development of precision medicines for oncology,...
Kura Oncology to Report Fourth Quarter and Full Year 2016 Financial Results
March 07, 2017 16:05 ET
|
Kura Oncology, Inc.
LA JOLLA, Calif., March 07, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company focused on the development of precision medicines for oncology,...
Kura Oncology to Participate in Three Upcoming Investor Conferences
February 09, 2017 16:05 ET
|
Kura Oncology, Inc.
LA JOLLA, Calif., Feb. 09, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company, today announced that Troy Wilson, Ph.D., J.D., President and Chief...
Kura Oncology Doses First Patient in Phase 2 Study of Tipifarnib in Chronic Myelomonocytic Leukemia
January 17, 2017 07:30 ET
|
Kura Oncology, Inc.
LA JOLLA, Calif., Jan. 17, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical stage biopharmaceutical company, today announced that the first patient has been dosed in its Phase...
Kura Oncology Appoints Steven Stein, M.D. to Board of Directors
January 03, 2017 16:05 ET
|
Kura Oncology, Inc.
LA JOLLA, Calif., Jan. 03, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical stage biopharmaceutical company, today announced the appointment of Steven H. Stein, M.D., to its...
Kura Oncology to Participate in the 5th Annual Gateway Conference
September 02, 2016 07:30 ET
|
Kura Oncology, Inc.
LA JOLLA, Calif., Sept. 02, 2016 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company, today announced its participation in the 2016 Gateway...